Holen Sie sich die Stockscreener-App
124.55
0.19%
-0.24
Schlusskurs vom Vortag:
$124.79
Offen:
$123.78
24-Stunden-Volumen:
438.18K
Relative Volume:
0.55
Marktkapitalisierung:
$7.29B
Einnahmen:
$507.44M
Nettoeinkommen (Verlust:
$-187.69M
KGV:
-38.08
EPS:
-3.271
Netto-Cashflow:
$-39.06M
1W Leistung:
+4.23%
1M Leistung:
+23.33%
6M Leistung:
+56.73%
1J Leistung:
+37.99%
1-Tages-Spanne:
$122.53
$127.00
1-Wochen-Bereich:
$118.57
$127.00
52-Wochen-Spanne:
$73.16
$130.23
Glaukos Corp Stock (GKOS) Company Profile
Firmenname
Glaukos Corp
Sektor
Branche
Telefon
949-367-9600
Adresse
1 GLAUKOS WAY, ALISO VIEJO, CA
Compare GKOS vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corp
|
124.55 | 7.30B | 507.44M | -187.69M | -39.06M | -3.271 |
ABT
Abbott Laboratories
|
96.00 | 168.22B | 45.13B | 6.28B | 7.40B | 3.5895 |
SYK
Stryker Corp
|
338.34 | 131.49B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
85.00 | 110.66B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
60.99 | 95.46B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.44 | 46.69B | 6.07B | 1.06B | 1.34B | 1.8063 |
Glaukos Corp Stock (GKOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-27 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-10-01 | Eingeleitet | Goldman | Buy |
| 2025-05-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-02-19 | Hochstufung | Mizuho | Neutral → Outperform |
| 2024-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-12-06 | Eingeleitet | UBS | Buy |
| 2024-12-02 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-05-06 | Hochstufung | Jefferies | Hold → Buy |
| 2023-12-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-12-04 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-11-28 | Eingeleitet | Truist | Buy |
| 2023-11-08 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-06-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-12-22 | Eingeleitet | Mizuho | Neutral |
| 2022-12-19 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-10-14 | Fortgesetzt | Stephens | Overweight |
| 2022-10-04 | Eingeleitet | Needham | Buy |
| 2022-07-12 | Hochstufung | Stifel | Hold → Buy |
| 2022-02-03 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2022-01-19 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-01-18 | Hochstufung | BTIG Research | Neutral → Buy |
| 2021-11-03 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2021-07-26 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2021-07-20 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2021-07-14 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-07-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-04-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Hochstufung | Citigroup | Sell → Neutral |
| 2020-12-09 | Eingeleitet | Oppenheimer | Perform |
| 2020-11-17 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2020-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-06-15 | Eingeleitet | Jefferies | Hold |
| 2020-03-05 | Eingeleitet | Citigroup | Sell |
| 2020-02-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-01-06 | Hochstufung | Berenberg | Hold → Buy |
| 2019-12-12 | Herabstufung | Wells Fargo | Outperform → Underperform |
| 2019-09-30 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2019-03-08 | Eingeleitet | BTIG Research | Neutral |
| 2018-08-30 | Eingeleitet | Berenberg | Hold |
| 2018-08-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-08-03 | Bestätigt | Stifel | Hold |
| 2018-06-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-04-13 | Herabstufung | Stifel | Buy → Hold |
| 2018-03-01 | Bestätigt | Cantor Fitzgerald | Buy |
| 2017-03-02 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-01-06 | Hochstufung | Stifel | Hold → Buy |
| 2016-10-27 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Glaukos Corp Aktie (GKOS) Neueste Nachrichten
Glaukos Corporation (GKOS) Stock Analysis: A Medical Device Innovator with 11.32% Potential Upside - DirectorsTalk Interviews
Glaukos’ Epioxa for keratoconus receives permanent J-code effective July 1, 2026 - Ophthalmology Times
Glaukos Releases Its 2025 Sustainability Report, Highlighting Key Milestones - VisionMonday.com
GLAUKOS Corp ($GKOS) CEO 2025 Pay Revealed - Quiver Quantitative
Glaukos receives new J-code for keratoconus treatment Epioxa By Investing.com - Investing.com Australia
Glaukos Wins Permanent J-Code for Epioxa Keratoconus Therapy - Yahoo Finance
Glaukos Announces the Release of its 2025 Sustainability Report - WFMZ.com
Glaukos Receives Permanent J-code for Epioxa™ - National Today
[ARS] GLAUKOS Corp SEC Filing - Stock Titan
Glaukos (NYSE: GKOS) 2026 proxy outlines board diversity, pay and ESG - Stock Titan
Glaukos Receives Permanent J-Code for Epioxa™ - National Today
Glaukos (GKOS) Secures J-Code for Epioxa Treatment - GuruFocus
Glaukos Receives Permanent J-code for Epioxa - National Today
Glaukos receives permanent J-code for Epioxa - TipRanks
Glaukos receives new J-code for keratoconus treatment Epioxa - Investing.com
[Form 4] GLAUKOS Corp Insider Trading Activity - Stock Titan
Glaukos Corporation (NYSE:GKOS) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Published on: 2026-04-14 04:05:55 - baoquankhu1.vn
Street Watch: What chart patterns are forming on Glaukos Corporation2026 Institutional & Weekly Return Optimization Plans - baoquankhu1.vn
Glaukos (NASDAQ: GKOS) affiliate sale reported in Form 144 - Stock Titan
(GKOS) Volatility Zones as Tactical Triggers - Stock Traders Daily
Glaukos sets April 29 earnings release, webcast after market close - Stock Titan
Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29 - Yahoo Finance
Citi Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $135 - Moomoo
A Look At Glaukos (GKOS) Valuation As Epioxa Showcased At ASCRS Annual Meeting - simplywall.st
Glaukos Stock 5-Day Winning Spree: Stock Climbs 13% - Trefis
Does Glaukos (GKOS) Using Epioxa at ASCRS Hint at a Broader Corneal-Health Strategy Shift? - Yahoo Finance
Glaukos to Present Multiple Scientific Abstracts at ASCRS Annual Meeting - National Today
Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refrac - PharmiWeb.com
Glaukos brings Epioxa symposium and 9 eye-care studies to ASCRS - Stock Titan
Capricorn Fund Managers Ltd Invests $6.78 Million in Glaukos Corporation $GKOS - MarketBeat
Q4 2024 Glaukos Corp Earnings Call Transcript - GuruFocus
Glaukos (NYSE: GKOS) CDO reports RSU tax withholding transactions - Stock Titan
Glaukos (NYSE: GKOS) CFO withholds 1,589 shares for RSU tax obligations - Stock Titan
Glaukos (GKOS) president uses 3,169 shares to cover tax withholding - Stock Titan
Glaukos (GKOS) CEO gifts 180,308 shares to family trust - Stock Titan
Glaukos Corp. Experiences Evaluation Revision Amidst Mixed Market Signals and Volatility - Markets Mojo
Cash per share of Glaukos Corp – DUS:6GJ - TradingView
Glaukos Corp (NYSE:GKOS) Shows High-Growth Momentum and Fits Key Trend Template Rules - ChartMill
Glaukos Corporation $GKOS Shares Acquired by Allspring Global Investments Holdings LLC - MarketBeat
GLAUKOS (GKOS) CDO has 5,798 shares withheld to cover RSU tax - Stock Titan
Glaukos Corporation (GKOS) Stock forecasts - Yahoo Finance UK
Glaukos Corporation (GKOS) Stock Forecasts - Yahoo Finance
GKOS PE Ratio & Valuation, Is GKOS Overvalued - intellectia.ai
SG Americas Securities LLC Purchases 49,492 Shares of Glaukos Corporation $GKOS - MarketBeat
Why Glaukos Stock Jumped Over 20% After-Hours Today - MSN
Alex Thurman: ‘Phenomenal Year’ for Glaukos - Orange County Business Journal
Price-Driven Insight from (GKOS) for Rule-Based Strategy - Stock Traders Daily
GKOS SEC FilingsGlaukos Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Aug Chart Watch: Does Glaukos Corporation stock have upside surprise potential2026 Major Catalysts & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Glaukos breaks ground on $80M R&D, manufacturing facility in Alabama - MSN
Finanzdaten der Glaukos Corp-Aktie (GKOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):